Cargando…

Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality

Detalles Bibliográficos
Autores principales:	Becker, Corina, Frey, Reiner, Hesse, Christiane, Unger, Sigrun, Reber, Michael, Mueck, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765651/ http://dx.doi.org/10.1186/2050-6511-14-S1-P7

Ejemplares similares

Effects of omeprazole and AlOH/MgOH on riociguat absorption
por: Becker, Corina, et al.
Publicado: (2013)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
por: Saleh, Soundos, et al.
Publicado: (2015)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults
por: DeJesus, Edwin, et al.
Publicado: (2019)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
por: Reiss, Cora, et al.
Publicado: (2013)

Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
por: Kalk, Philipp, et al.
Publicado: (2009)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study
por: Bonderman, Diana, et al.
Publicado: (2014)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Muscle proportionality: The proportionality of skeletal muscle before and after intervention
por: Jones, Brian A, et al.
Publicado: (2015)

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian
por: Kanefendt, Friederike, et al.
Publicado: (2022)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Specific IgE for foods in a Romanian adult population
por: Deleanu, Diana, et al.
Publicado: (2011)

Survey proportion of safety and ergonomics parameters in Sabzevar preschool centers
por: Abareshi, Fateme, et al.
Publicado: (2019)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Statistical modelling of biomarkers incorporating non-proportional effects for survival data
por: Stephen, Jacqueline, et al.
Publicado: (2013)

Genetic diversity and high proportion of intersubtype recombinants of HIV-1 in urban Cameroon
por: Machuca, Ana, et al.
Publicado: (2006)

What proportion of calories given to critically ill patients come from propofol?
por: Abi Musa Asa'ari, AKA, et al.
Publicado: (2015)

P02.183. Comparing the bioavailability of two forms of lipoic acid in multiple sclerosis
por: Salinthone, S, et al.
Publicado: (2012)

The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
por: Fricker, Simon, et al.
Publicado: (2012)

Assessing violations of the proportional hazards assumption in Cox regression: does the chosen method matter?
por: Hiller, Louise, et al.
Publicado: (2015)

Axon reflex-mediated vasodilation is reduced in proportion to disease severity in familial amyloid polyneuropathy
por: Kuntzer, Thierry, et al.
Publicado: (2015)

Firing rate control of a neuron using a linear Proportional-Integral (PI) controller
por: Miranda-Dominguez, Oscar, et al.
Publicado: (2010)

0989. Accuracy of delivered airway pressure during proportional assist ventilation +. A bench study
por: Beloncle, F, et al.
Publicado: (2014)

Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats
por: Wahajuddin, et al.
Publicado: (2011)

Identification of putative allergens from school shark, a cartilaginous food fish
por: Golla, Hemashree, et al.
Publicado: (2014)

Predictable implications of random photon absorption for photoreceptors' gain control
por: Song, Zhuoyi, et al.
Publicado: (2015)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_945hrnia69afiir2jtq561ubck